Hepatocellular carcinoma (HCC) · Entecavir — chronic HBV antiviral suppression

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`REG-HBV-ENTECAVIR`

ID	`IND-CHRONIC-HBV-PREVENTION-ANTIVIRAL`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-HCC`
Sources	`SRC-AASLD-HBV-2024` `SRC-AASLD-HCC-2023` `SRC-EASL-HBV-2025`

Notes

STUB — v0.2-A continuation. Antiviral Regimen authoring (entecavir / tenofovir) is v0.2-A backlog.

Used By

Actionability

BMA-HBV-DNA-MONITORING-ANTIVIRAL-RESPONSE - Quantitative HBV DNA tracks response during nucleos(t)ide-analogue (NA) therapy with ente...

Contraindications

CI-ENTECAVIR-HIV-MONOTHERAPY - CI-ENTECAVIR-HIV-MONOTHERAPY
CI-TENOFOVIR-SEVERE-RENAL - CI-TENOFOVIR-SEVERE-RENAL

Indication

IND-CHRONIC-HBV-PREVENTION-OBSERVATION - IND-CHRONIC-HBV-PREVENTION-OBSERVATION

Red flag

RF-CHRONIC-HBV-MALIGNANCY-PREVENTION - Chronic Hepatitis B infection (HBsAg+ ≥6 months OR HBV-DNA detectable ≥6 months) in an in...